

## **OPEN PEER REVIEW REPORT 1**

Name of journal: Neural Regeneration Research

Manuscript NO: NRR-D-18-00811

Title: Vacuolar protein sorting protein 41 (VPS41) at an intersection of endosomal traffic in

neurodegenerative disease

Reviewer's Name: Stefano Di Santo Reviewer's country: Switzerland Date sent for review: 2018-11-23

**Date reviewed:** 2018-12-04

Review time: 11 days

## **COMMENTS TO AUTHORS**

The manuscript from Griffin and co-workers is a very informative and well written Review. The authors highlight recent findings in C. Elegans regarding common molecular hallmarks of neurodegenerative disorders as Parkinson's and Alzheimer's diseases.

I have only minor considerations:

- The reference Griffin E et al., 2017 cited at the end of the manuscript is wrong.
- Please include in the figure legend the explanation of the abbreviations.



## **OPEN PEER REVIEW REPORT 2**

Name of journal: Neural Regeneration Research

Manuscript NO: NRR-D-18-00811

Title: Vacuolar protein sorting protein 41 (VPS41) at an intersection of endosomal traffic in

neurodegenerative disease

Reviewer's Name: Robert L. Haining

Reviewer's country: USA

Date sent for review: 2018-11-23

**Date reviewed:** 2018-12-07

Review time: 14 days

## **COMMENTS TO AUTHORS**

This review is at the forefront of where we need to be to understand neurological diseases. It's strength lies in its brevity and because it addresses a critical missing link in our understanding.

I'm not finding much in the way of weaknesses that could really be addressed. It is a complicated subject, and the authors seem to do the best they can to make the links clear. This should be published.

Successful treatment and/or prevention of neurological diseases will require a thorough understanding of these pathways, of course. I found this review to be very timely, concise, and useful. This is one of those papers where upon review, one struggles to identify something intelligent to criticize. All I can really say here is I applaud your efforts and hope you have the funding to continue.